CytoReason secures $80m investment to expand disease modeling technologies
In a significant boost for the field of computational disease modeling, CytoReason announced an $80 million investment led by high-profile entities such as OurCrowd, NVIDIA Corporation (Nasdaq: NVDA), Pfizer Inc. (NYSE: PFE), and Thermo Fisher Scientific Inc. (NYSE: TMO). This new funding aims to enhance CytoReason’s development and application of predictive models across various medical […]